IRIS
BERARDI, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.265
EU - Europa 13.928
AS - Asia 12.176
SA - Sud America 2.879
Continente sconosciuto - Info sul continente non disponibili 1.129
AF - Africa 716
OC - Oceania 21
Totale 61.114
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.688
RU - Federazione Russa 4.100
SG - Singapore 4.006
VN - Vietnam 2.461
IT - Italia 2.316
BR - Brasile 2.262
CN - Cina 1.964
UA - Ucraina 1.357
HK - Hong Kong 1.292
DE - Germania 1.181
IE - Irlanda 1.078
SE - Svezia 845
FR - Francia 720
FI - Finlandia 661
TR - Turchia 584
GB - Regno Unito 517
DK - Danimarca 457
IN - India 391
BD - Bangladesh 353
CI - Costa d'Avorio 305
CA - Canada 294
KR - Corea 272
AR - Argentina 233
NL - Olanda 162
MX - Messico 151
PL - Polonia 135
JP - Giappone 132
ZA - Sudafrica 123
MA - Marocco 116
ID - Indonesia 110
IQ - Iraq 109
EC - Ecuador 100
CO - Colombia 88
PK - Pakistan 78
BE - Belgio 69
ES - Italia 69
AT - Austria 63
UZ - Uzbekistan 54
PH - Filippine 50
VE - Venezuela 48
CL - Cile 47
PY - Paraguay 39
KE - Kenya 32
CR - Costa Rica 31
RO - Romania 31
SA - Arabia Saudita 31
TN - Tunisia 31
AZ - Azerbaigian 30
MY - Malesia 30
PE - Perù 30
EG - Egitto 28
JO - Giordania 26
DZ - Algeria 25
AE - Emirati Arabi Uniti 24
LT - Lituania 24
JM - Giamaica 23
KZ - Kazakistan 23
NP - Nepal 20
UY - Uruguay 19
CZ - Repubblica Ceca 18
TH - Thailandia 17
HN - Honduras 15
AU - Australia 14
IL - Israele 14
SK - Slovacchia (Repubblica Slovacca) 14
TW - Taiwan 14
EU - Europa 13
AL - Albania 12
KG - Kirghizistan 12
CH - Svizzera 11
PR - Porto Rico 11
PS - Palestinian Territory 10
PT - Portogallo 10
RS - Serbia 10
BG - Bulgaria 9
BH - Bahrain 9
BO - Bolivia 9
BY - Bielorussia 9
DO - Repubblica Dominicana 9
ET - Etiopia 9
LB - Libano 9
GR - Grecia 8
NI - Nicaragua 8
SN - Senegal 8
TT - Trinidad e Tobago 8
NG - Nigeria 7
NZ - Nuova Zelanda 7
BA - Bosnia-Erzegovina 6
GT - Guatemala 6
HR - Croazia 6
IR - Iran 6
KW - Kuwait 6
LY - Libia 6
OM - Oman 6
SI - Slovenia 6
CY - Cipro 5
GE - Georgia 5
PA - Panama 5
SV - El Salvador 5
XK - ???statistics.table.value.countryCode.XK??? 5
Totale 59.915
Salva come PNG Salva come JPEG
Città #
Ashburn 4.838
Singapore 2.592
Dallas 2.580
Chandler 2.048
Jacksonville 1.510
San Jose 1.491
Fairfield 1.488
Council Bluffs 1.305
Hong Kong 1.248
Des Moines 1.180
Dublin 1.069
Boardman 1.004
Ho Chi Minh City 784
New York 782
Wilmington 735
Woodbridge 660
Seattle 651
Houston 619
Hanoi 568
The Dalles 523
Ann Arbor 495
Beijing 492
Los Angeles 489
Cambridge 480
Lauterbourg 416
Princeton 390
Lawrence 388
Munich 367
San Mateo 364
Moscow 343
Abidjan 305
Helsinki 288
Hefei 231
Milan 229
Centro 217
São Paulo 210
Santa Clara 203
Buffalo 188
San Diego 184
Chicago 177
London 144
Rome 137
Turku 137
Da Nang 132
Orem 126
Turin 124
Ancona 123
Warsaw 120
Haiphong 119
Phoenix 117
Washington 110
Pune 106
Tokyo 103
Chennai 81
Montreal 81
Rio de Janeiro 79
Johannesburg 71
Guangzhou 70
Shanghai 70
Frankfurt am Main 69
Denver 68
Brooklyn 67
Brussels 65
Atlanta 63
Nuremberg 60
Columbus 57
Vancouver 56
Poplar 53
Mexico City 52
Miano 52
Belo Horizonte 50
Hải Dương 49
Stockholm 47
Tashkent 46
Boston 45
Elk Grove Village 45
Salt Lake City 43
Amsterdam 42
Baghdad 41
Manchester 41
Marche 41
Brasília 40
Falls Church 40
Biên Hòa 39
San Francisco 39
Toronto 39
Norwalk 38
Mumbai 35
Curitiba 34
Wuhan 34
Dhaka 33
Quito 33
Naples 32
Porto Alegre 32
Urbisaglia 31
Thái Nguyên 29
Tolentino 29
Ankara 28
Nairobi 28
Baku 27
Totale 37.973
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 2.293
Contrasting Digital Fake News in Health: an Interdisciplinary Approach 834
Contrasting Fake News in Oncology: The First Declaration of Good Communication 816
The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer 285
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy 279
Metabolic phenotype of bladder cancer 268
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 256
Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature 243
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 229
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 227
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 225
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 215
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 213
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 209
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 205
Are liver nested stromal epithelial tumors always low aggressive? 203
Extended efficacy and safety Denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. 203
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 203
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 202
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 201
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 200
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 199
1621P miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study 198
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 197
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 194
Role of DCE-MR in predicting breast cancer subtypes. 192
Optimal management of resected gastric cancer 189
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 189
Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia 189
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 189
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 186
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 185
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 184
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 184
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 183
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 178
5-Fluorouracil pharmacogenomics: still rocking after all these years? 177
Developments in the management of advanced soft-tissue sarcoma –€“ Olaratumab in context 177
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 174
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 173
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 172
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 171
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 171
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 171
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 169
A cost-benefit analysis of chemotherapy for gastric cancer. 169
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 169
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 169
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 169
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 168
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 168
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 167
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data 165
Gender Differences and Outcomes in Melanoma Patients 165
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 164
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 164
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 164
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 164
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 163
Electrolyte disorders in cancer patients: a systematic review 163
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 160
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 160
Squamous cell carcinoma of the lung: clinical criteria for treatment strategy 158
Lynphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. 158
Adjuvant treatment after surgical resection 158
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 156
Medical treatment for cholangiocarcinoma 156
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study 156
Seminoma Retroperitoneal Relapse 23 Years After Surgery 156
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 155
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 155
Benefits and limitations of a multidisciplinary approach in cancer patient management 154
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 154
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 154
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 153
Managing hyponatremia in lung cancer: latest evidence and clinical implications 153
High CTLA-4 expression correlates with poor prognosis in thymoma patients 153
Randomized active-controlled phase 2 study of Denosumab efficacy and safety in patients with breast cancer-related bone metastases. 152
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 152
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 152
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 152
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 151
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 150
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 150
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions 150
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 149
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 149
Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex 148
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 148
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 148
Gender differences and outcome of melanoma patients 147
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial 147
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 147
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 147
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 146
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 146
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 146
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer 146
Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer 145
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma 145
Totale 20.953
Salva come PNG Salva come JPEG
Categoria #
all - tutte 269.908
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 269.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.244 0 0 78 98 42 224 124 209 303 207 328 631
2022/20236.355 518 648 404 531 338 1.618 2 325 1.357 58 411 145
2023/20243.659 580 83 234 408 574 877 52 132 10 131 51 527
2024/20258.278 851 754 371 158 339 357 692 323 1.948 658 824 1.003
2025/202626.712 1.508 1.944 2.531 2.583 2.424 1.579 4.136 2.244 3.946 1.974 826 1.017
2026/20272.608 1.111 1.199 298 0 0 0 0 0 0 0 0 0
Totale 61.114